Just as it did in 2011, Foundation Medicine has inked its fourth partnership this year. The Cambridge cancer diagnostics company’s latest partnership agreement is with AstraZeneca (AZN:LN), a biopharmaceutical company headquartered in London.

Together, the companies are working to identify alterations in cancer-related tumor genes that could potentially predict a person’s response or resistance to specific medicine.